Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002309 · ClinicalTrials.gov registry record · NA

A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients

A NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by Pfizer.

Completed
Registry status
NA
Development phase
3
Study locations

NCT00002309: Completed NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by Pfizer.

NCT00002309 is a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection that has completed, run by Pfizer. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002309, a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, has completed, sponsored by Pfizer.

COMPLETED
Registry status
NA
Development phase
3
Study locations

Study Summary

To evaluate the efficacy and safety of azithromycin administered once a week in the prevention of disseminated Mycobacterium avium complex (MAC) in severely immunocompromised HIV-infected patients with a CD4 count \< 100 cells/mm3.

Conditions Studied

HIV Infections Mycobacterium Avium-Intracellulare Infection

Interventions

  • DRUG Azithromycin

Study Locations (3)

California

  • San Diego Naval Hosp - San Diego

North Carolina

  • Womack Army Med Ctr / Med Clinic - Fort Bragg

Texas

  • United States Air Force Med Ctr - Lackland Air Force Base

Trial Details

FieldValue
Phase NA
Pfizer

1,845 total trials

What the finished NCT00002309 record still lists

NCT00002309 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Azithromycin is the first listed.

NCT00002309 reports a single indexed study location in California, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT00002309 about?

NCT00002309 is a clinical study titled "A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients". To evaluate the efficacy and safety of azithromycin administered once a week in the prevention of disseminated Mycobacterium avium complex (MAC) in severely immunocompromised HIV-infected patients with a CD4 count \< 100 cells/mm3.

What is the current status of trial NCT00002309?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002309 study?

This clinical trial studies the following conditions: HIV Infections, Mycobacterium Avium-Intracellulare Infection.

What interventions are being tested in trial NCT00002309?

The interventions under investigation include: Azithromycin (DRUG).

Who is sponsoring clinical trial NCT00002309?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002309 being conducted?

This trial has 3 study locations across California, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002309, the US trial registry maintained by the National Library of Medicine. NCT00002309 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.